64B16-26.204: Licensure by Endorsement
PURPOSE AND EFFECT: The Board proposes the rule amendment to remove the requirement for applicants by endorsement to have completed an HIV/AIDS course as part of the application.
SUMMARY: The requirement for applicants by endorsement to have completed an HIV/AIDS course as part of the application will be removed from the rule.
SUMMARY OF STATEMENT OF ESTIMATED REGULATORY COSTS: No Statement of Estimated Regulatory Cost was prepared.
Any person who wishes to provide information regarding a statement of estimated regulatory costs, or provide a proposal for a lower cost regulatory alternative must do so in writing within 21 days of this notice.
SPECIFIC AUTHORITY: 456.033, 465.005 FS.
LAW IMPLEMENTED: 456.013(1), (7), 456.033, 465.007, 465.0075, 465.022 FS.
IF REQUESTED WITHIN 21 DAYS OF THE DATE OF THIS NOTICE, A HEARING WILL BE SCHEDULED AND ANNOUNCED IN FAW.
THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Rebecca R. Poston, Executive Director, Board of Pharmacy/MQA, 4052 Bald Cypress Way, Bin #C04, Tallahassee, Florida 32399-3253
THE FULL TEXT OF THE PROPOSED RULE IS:
64B16-26.204 Licensure by Endorsement.
An applicant for licensure by endorsement must be at least 18 years of age and a recipient of a degree from a school or college of pharmacy accredited by an accrediting agency recognized and approved by the United States Office of Education.
(1) through (2) No change.
(3) The applicant must submit satisfactory proof of completion of the following:
(a) A Board approved course of no less than three (3) contact hours on HIV/AIDS covering the subjects set forth in Rule 64B16-26.6011, F.A.C. The course shall be completed no earlier than 12 months prior to application.
(a)(b) No change.
(4) through (8) No change.
Specific Authority 456.033, 465.005, 465.0075 FS. Law Implemented 456.013(1), 456.033, 465.007, 465.0075, 465.022 FS. HistoryNew 11-8-01, Amended 1-11-05,________.
